relation: http://publicatio.bibl.u-szeged.hu/28568/
title: Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice : results of a multicentric, retrospective study
creator:  Váradi Melinda
creator:  Kordáné Horváth Orsolya
creator:  Módos Orsolya
creator:  Fazekas Tamás
creator:  Grunewald Camilla M
creator:  Niegisch Günter
creator:  Krafft Ulrich
creator:  Grünwald Viktor
creator:  Hadaschik Boris
creator:  Olah Csilla
creator:  Maráz Anikó
creator:  Furka Andrea
creator:  Szűcs Miklós
creator:  Nyirády Péter
creator:  Szarvas Tibor
subject: 03.02. Klinikai orvostan
description: Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n = 210, n = 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model.
date: 2023
type: Folyóiratcikk
type: PeerReviewed
format: text
identifier: http://publicatio.bibl.u-szeged.hu/28568/1/s41598-023-44103-9.pdf
identifier:     Váradi Melinda;  Kordáné Horváth Orsolya;  Módos Orsolya;  Fazekas Tamás;  Grunewald Camilla M;  Niegisch Günter;  Krafft Ulrich;  Grünwald Viktor;  Hadaschik Boris;  Olah Csilla;  Maráz Anikó;  Furka Andrea;  Szűcs Miklós;  Nyirády Péter;  Szarvas Tibor: Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice : results of a multicentric, retrospective study.   SCIENTIFIC REPORTS, 13 (1).   ISSN 2045-2322 (2023)     
identifier: doi:10.1038/s41598-023-44103-9
relation: https://doi.org/10.1038/s41598-023-44103-9
relation: 34199654
language: eng